Mount Sinai Adopts SOPHiA AI Platform for Cancer Genomic Testing
Mount Sinai will deploy SOPHiA GENETICS’ AI platform to improve genomic testing, reduce analysis time, and scale cancer diagnostics workflows.
Mount Sinai Health System will deploy an AI-driven genomics platform from SOPHiA GENETICS to expand cancer testing and reduce analysis time, according to a press release.
Mount Sinai will adopt the SOPHiA DDM platform across its molecular pathology workflows for blood cancers and solid tumors. The system processes next-generation sequencing (NGS) data and identifies complex genomic variants while consolidating steps in the analysis pipeline.
The health system treats more than 4,000 oncology patients annually and operates as a National Cancer Institute-designated Comprehensive Cancer Center, supporting a high volume of cancer diagnostics and laboratory testing, as highlighted in the announcement.
The platform reportedly integrates sequencing analysis, variant detection, and interpretation into a single workflow. It reduces hands-on analysis time and improves testing turnaround, allowing clinicians to act on results earlier in the care process.
Jane Houldsworth, Director of Molecular Oncology Pathology at Mount Sinai Health System, said, “Leveraging SOPHiA DDM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care.”
The system is designed to detect a wide range of genomic variants, including complex alterations that require manual interpretation in standard workflows. It also consolidates analysis steps typically handled across separate tools and software systems in laboratory environments.
Mount Sinai will operate the platform within its CLIA-certified, CAP-accredited laboratory as a laboratory developed test (LDT), following internal validation protocols and established compliance standards.
The deployment connects Mount Sinai to a network of more than 990 institutions using SOPHiA GENETICS’ platform globally.
John Carey, Managing Director, North America at SOPHiA GENETICS, said the platform is designed to deliver “faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology.”
The collaboration was announced in San Diego during the AACR Annual Meeting 2026, where new developments in cancer research and treatment were presented.